Degarelix is a well-known LHRH antagonist that is commonly used in advanced prostate cancer, with the advantage that it avoids tumour flare-up with a faster depression of testosterone levels compared to LHRH agonists [13]. The gene discussed is GNRH1; the disease is prostate cancer.